Who We Are
Founded in 2008, BioVantra is an innovative anatomic pathology and molecular diagnostics company positioned to become a leader in the translation, development, and delivery of genomic tests specifically designed to assist physicians and patients better managing cancer and other chronic diseases.
Using advanced technology, BioVantra identifies and validates small-to-medium sets of genomic markers used to make practical, meaningful, and easy-to-use diagnostic, prognostic and targeted therapy tests for clinicians, researchers, and pharmaceutical development.
We understand the importance of accurate, timely diagnostic test results and actionable healthcare information. Our commitment to these values helped ensure superior patient care and increased client satisfaction.
Miles Locke (President and CEO)
Miles Locke joined BioVantra in 2010 as Vice President of Business Development and was appointed as President and CEO in 2021. Mr. Locke’s experience includes leadership positions in operations, purchasing and logistics, regulatory oversight, and new laboratory test development and validation.
In his current position, Mr. Locke is responsible for providing effective leadership for delivering valuable clinical laboratory services and the overall operation and administration of the laboratory. In addition, he directs BioVantra’s translational genomic initiatives to ensure that clinicians have the most up-to-date information to address each patient’s specific needs and clinical situation.
Miles received his Bachelor of Science in Biology and Chemistry from the University of Florida.
Joseph A. Migliozzi, M.D., PhD. (Medical Director)
Dr. Migliozzi serves as the Medical Director at BioVantra. He is a recognized expert in the field of urological and molecular pathology.
Dr. Migliozzi received his Ph.D. and M.D. degree from the University of Illinois in Chicago, Illinois. Subsequently, he completed a residency in anatomic and clinical pathology at Northwestern University in Chicago, Illinois, followed by a fellowship in surgical pathology at UCLA in Los Angeles, California. Dr. Migliozzi is board certified in anatomic pathology and clinical pathology by the American Board of Pathology.
Before joining BioVantra, Dr. Migliozzi compiled over four decades of experience in the academic, corporate, and private sectors. He is an active and contributing member of the International Academy of Pathology and College of American Pathologists.
Dr. Migliozzi is responsible for the overall operation and administration of BioVantra, including the employment of competent personnel to perform test procedures, record and report test results promptly, accurately, and proficiently, and ensure compliance with the applicable regulations. In addition, he plays a critical role in the development and execution of BioVantra’s clinical development strategy.
Javier Romano BSc, RDMS (Integrative Services)
Javier Romano joined BioVantra in 2014 as a sales affiliate. Since joining BioVantra, he has been a contributor to the growth of the company through establishing relationships with customers, guiding product and service line extensions, and entry into new markets.
Today, he is responsible for directing client integrative services activities. Mr. Romano assists our urology clients to develop customized pathology solutions that support the continuum of patient care, beginning with disease risk assessment and diagnosis and culminating with disease stratification and management.
Mr. Romano has more than 25 years of experience in the urologic imaging, pathology, and therapeutic sectors. Before joining BioVantra, he founded American Diagnostic Imaging. A mobile diagnostic imaging company focused on MRI/ultrasound fusion targeted prostate biopsy.
Mr. Romano holds a bachelor’s degree in Health Service Administration from Barry University and is a certified medical sonographer (RDMS).